drugset / Trial / NCT07354620

A Pilot Study on Reverse Aging (The REVERSE Study)

NCT07354620

Phase 0 Active not recruiting 52 enrolled The Christ Hospital
RandomizedParallel-groupOpen-labelPrevention

Summary

Aging can be defined as a time-dependent functional decline in physiological function, which may increase the vulnerability to diseases and eventually death. The question is whether aging is a normal process, or exists as an "uber-illness?" Work done by Dr Sinclair at Harvard suggests the latter. Dr. Sinclair feels people should be able to age-in-place, or even reverse age. Aging is arguably the single biggest risk factor for all acquired and chronic diseases. Delaying the aging rate by 7 years would cut the incidence of chronic disease in half! Up until know the effects of anti-aging would need longitudinal studies until death. Now, with the advent of a 3rd generation OMIC Age clock, there is a way to assess if an intervention is changing the rate of aging and other methylation patterns associated with aging.

Timeline

Start
2025-02-15
Primary completion
2026-02
Completion
2026-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Sirolimus Small molecule 6 mg